Latest Articles
Accenture employee wins appeal after dismissal under ‘up or elsewhere’ policy - People Management
Accenture employee wins appeal after dismissal under ‘up or elsewhere’ policy People Management
Published: Feb. 2, 2026, 1:01 p.m.
Complication Rates and Management in Sentinel Lymph Node Biopsy for Endometrial Cancer: A Retrospective Cohort Study - Frontiers
Complication Rates and Management in Sentinel Lymph Node Biopsy for Endometrial Cancer: A Retrospective Cohort Study Frontiers
Published: Jan. 30, 2026, 6:10 p.m.
Management of Suspected Stage IVA Endometrial Cancer With Rectosigmoid Involvement Using Neoadjuvant Chemotherapy and Interval Surgery - Cureus
Management of Suspected Stage IVA Endometrial Cancer With Rectosigmoid Involvement Using Neoadjuvant Chemotherapy and Interval Surgery Cureus
Published: Jan. 21, 2026, 1:51 p.m.
Proteomics International pivots to sales with management shake-up - The Age
Proteomics International pivots to sales with management shake-up The Age
Published: Jan. 14, 2026, 4:13 a.m.
Proteomics International pivots to sales with management shake-up - Brisbane Times
Proteomics International pivots to sales with management shake-up Brisbane Times
Published: Jan. 14, 2026, 4:13 a.m.
Integrating IVF and Surgical Management in Endometriosis-Associated Infertility: A Review - springermedicine.com
Integrating IVF and Surgical Management in Endometriosis-Associated Infertility: A Review springermedicine.com
Published: Jan. 13, 2026, 5:03 a.m.
FOGSI Expert Consensus Review Redefines Landscape of Endometriosis Management with Elagolix: 5 Key Takeaways - Medical Dialogues
FOGSI Expert Consensus Review Redefines Landscape of Endometriosis Management with Elagolix: 5 Key Takeaways Medical Dialogues
Published: Jan. 12, 2026, 9:24 a.m.
Endometrial Cancer: Toxicity Management and Treatment Persistence with Lenvatinib-Pembrolizumab - OncLive
Endometrial Cancer: Toxicity Management and Treatment Persistence with Lenvatinib-Pembrolizumab OncLive
Published: Dec. 26, 2025, 1:19 p.m.
Safety and Optimal AE Management of Lenvatinib Plus Pembrolizumab in Endometrial Cancer - Targeted Oncology
Safety and Optimal AE Management of Lenvatinib Plus Pembrolizumab in Endometrial Cancer Targeted Oncology
Published: Dec. 22, 2025, 1:15 p.m.
Mismatch Repair Deficiency Profiling and Its Impact on Management and Prognosis in Endometrial Cancer Patients: A Comprehensive Update - Cureus
Mismatch Repair Deficiency Profiling and Its Impact on Management and Prognosis in Endometrial Cancer Patients: A Comprehensive Update Cureus
Published: Dec. 16, 2025, 12:29 p.m.
Link copied to clipboard!